胃乐新联合兰索拉唑肠溶胶囊治疗消化性胃溃疡的效果分析

Effect analysis of Weilexin combined with lansoprazole enteric-coated capsules in the treatment of pepticgastriculcer

目的分析胃乐新联合兰索拉唑肠溶胶囊治疗消化性胃溃疡的效果。方法 89例消化性胃溃疡患者,将其随机分为对照组(43例)与观察组(46例)。对照组给予胃乐新治疗,观察组在对照组基础上加用兰索拉唑治疗。比较两组治疗效果。结果治疗前两组腹部隐痛、嗳气反酸、恶心呕吐、腹泻腹胀积分比较差异均无统计学意义(P>0.05);治疗后两组各症状积分均较治疗前明显下降,且观察组低于对照组,差异均具有统计学意义(P<0.05)。对照组不良反应发生率9.30%略低于观察组13.04%,但差异无统计学意义(P>0.05)。结论以胃乐新与兰索拉唑联合治疗消化性胃溃疡效果显著,能有效减轻患者溃疡症状,且不良反应发生率低,安全性高。

Objective To analyze the effect of Weilexin combined with lansoprazole enteric-coated capsules in the treatment of pepticgastriculcer. Methods A total of 89 pepticgastriculcer patients were randomly divided into control group（43 cases） and observation group（46 cases）. The control group received Weilexin for treatment, and the observation group received lansoprazole on the basis of the control group. Treatment effect was compared in two groups. Results There was no statistically significant difference in abdominal dull pain, belching and acid regurgitation, nausea and vomiting, diarrhea and abdominal distension integral before treatment between two groups（P0.05）. Both groups had obvious decline in each symptom integral after treatment than before treatment, and the observation group had lower integral than the control group. Their difference had statistical significance（P0.05）. The control group had incidence of adverse reactions as 9.30%, which was lower than 13.04% in the observation group, but the difference had no statistical significance（P0.05）. Conclusion Combination of Weilexin and lansoprazole shows significant effect in the treatment of pepticgastriculcer, and it can effectively relieve ulcer symptoms in patients with low incidence of adverse reactions and high safety.